MAPT and Alzheimer disease: Considering that multiple alterations are concomitant to Aβ and tau aberrant processing in AD (Ferrer, 2012), compounds with pleiotropic activity which will target in parallel several processes that play key roles in AD are expected to yield greater benefits than those obtained by current therapies (Bolognesi et al., 2009; Frautschy and Cole, 2010).